Gilead Sciences (NASDAQ:GILD) Insider Sells $4,775,400.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $170.55, for a total value of $4,775,400.00. Following the transaction, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

  • On Thursday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $156.22, for a total value of $468,660.00.
  • On Tuesday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $144.22, for a total transaction of $432,660.00.

Gilead Sciences Stock Down 1.4%

GILD opened at $166.53 on Friday. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The stock has a market cap of $206.55 billion, a P/E ratio of -52.70 and a beta of 0.35. The stock’s 50 day moving average price is $156.80 and its 200 day moving average price is $142.34.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.47 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.97 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on GILD shares. HSBC increased their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $175.00 target price on shares of Gilead Sciences in a report on Monday, November 2nd. Wells Fargo & Company upped their price objective on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Finally, Morgan Stanley upped their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.63.

View Our Latest Stock Analysis on Gilead Sciences

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raffa Wealth Management LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at approximately $28,000. PFS Partners LLC boosted its stake in Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 96 shares in the last quarter. Persistent Asset Partners Ltd acquired a new position in Gilead Sciences in the 2nd quarter worth about $25,000. Laurel Wealth Advisors LLC acquired a new position in shares of Gilead Sciences in the third quarter worth approximately $29,000. Finally, Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $25,000. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Recommended Stories

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.